Impressive: “In this study, omalizumab demonstrated an 87% decrease in exacerbation rate from baseline and a significant reduction in the proportion of patients experiencing ≥1 exacerbation over 12 months.” What about cost effectiveness? 🤔 https://t.co/gn
1,121 followers
1,515 followers
Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study | World Allergy Organization Journal | Full Text https://t.co/FWAP7cjMWV, see more https://t.co/DYNr6PkPQa
1,025 followers
RT @worldallergy: Read the latest article published in the WAO Journal: Improvement of patient-reported outcomes in severe allergic asthma…
156 followers